Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
Gabriela MarsavelaJenny H J LeeLeslie CalapreStephen Q WongMichelle R PereiraAshleigh C McEvoyAnna L ReidCleo RobinsonLydia WarburtonAfaf AbedMuhammad A KhattakTarek M MeniawySarah-Jane DawsonShahneen SandhuMatteo S CarlinoAlexander M MenziesRichard A ScolyerGeorgina V LongBenhur AmanuelMichael MillwardMelanie R ZimanHelen RizosElin Solomonovna GrayPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Pretreatment ctDNA is a reliable indicator of patient outcome in the first-line ICI treatment setting, but not in the second-line ICI setting, especially in patients pretreated with BRAF/MEK inhibitors. Preliminary evidence indicated that treatment-naïve patients with high ctDNA may preferentially benefit from combined ICIs.